Elanco Animal Health Incorporated financials
$22.61+0.71%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.37B | $1.37B | $1.14B | $1.14B | $1.24B | $1.19B | $1.02B | $1.03B | $1.18B | $1.21B | $1.03B | $1.07B |
| Gross profit | $798.0M | $785.0M | $589.0M | $607.0M | $713.0M | $684.0M | $519.0M | $538.0M | $689.0M | $690.0M | $519.0M | $581.0M |
| Gross margin | 58.3% | 57.3% | 51.5% | 53.4% | 57.5% | 57.3% | 50.9% | 52.2% | 58.2% | 57.3% | 50.1% | 54.4% |
| Operating income | $115.0M | $144.0M | -$183.0M | $2.0M | $73.0M | $100.0M | $1.0M | -$22.0M | $35.0M | $87.0M | -$101.0M | -$1.02B |
| Net income | $54.0M | $57.0M | -$276.0M | -$34.0M | $11.0M | $67.0M | -$8.0M | $364.0M | -$50.0M | $32.0M | -$141.0M | -$1.10B |
| Net margin | 3.9% | 4.2% | −24.1% | −3.0% | 0.9% | 5.6% | −0.8% | 35.3% | −4.2% | 2.7% | −13.6% | −102.6% |
| Diluted EPS | $0.11 | $0.11 | $-0.56 | $-0.07 | $0.02 | $0.13 | $-0.02 | $0.73 | $-0.10 | $0.06 | $-0.29 | $-2.22 |
| EBITDA | $295.0M | $332.0M | $193.0M | $203.0M | $243.0M | $270.0M | $172.0M | $165.0M | $277.0M | $299.0M | -$65.0M | $215.0M |
| Operating cash flow | $277.0M | $13.0M | $108.0M | $219.0M | $237.0M | -$4.0M | $177.0M | $162.0M | $200.0M | $2.0M | $157.0M | $198.0M |
| Free cash flow | $244.0M | -$38.0M | $46.0M | $127.0M | $180.0M | -$69.0M | $130.0M | $120.0M | $166.0M | -$22.0M | $116.0M | $165.0M |
| Diluted shares | 505.9M | 506.0M | 489.6M | 496.8M | 500.1M | 499.1M | 501.3M | 497.7M | 494.2M | 496.0M | 491.1M | 492.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $530.0M | $428.0M | $545.0M | $505.0M | $539.0M | $487.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $3.92B | $3.99B | $4.02B | $4.02B | $4.21B | $4.39B |
| Total assets | $13.56B | $13.22B | $13.36B | $13.55B | $13.74B | $12.94B |
| Total liabilities | $6.97B | $6.72B | $6.81B | $6.80B | $6.97B | $6.59B |
| Shareholders' equity | $6.59B | $6.50B | $6.55B | $6.75B | $6.78B | $6.35B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology